Clinical Trial

Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML

Study acronym: PALOMA
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 11, 2023 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
To compare the event-free survival at 2 years of CPX-351 vs. conventional care regimens before allogeneic blood cell transplantation as first line treatment in patients with higher risk MDS and oligoblastic AML.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2019-08-16; most recent amendment 2023-10-10.
Status change: Not Yet Recruiting → Recruiting 2019-09-20
Trial Details
NCT Number NCT04061239
Lead Sponsor GWT-TUD GmbH
Conditions MDS, AML
Enrollment 150 participants
Start Date 2019-08-19
Primary Completion 2026-03 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2023-10-11